Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

consisted of $5.1 million of royalty fees earned from the commercial sales of memantine by Merz and its marketing partners in the United States and certain European countries, $3.2 million from the sale of NTI's rights and assets related to XERECEPT to Celtic, and $4.0 million from the reimbursement of the direct expenses incurred for the services provided to Celtic.

Research and development expenses of $26.7 million in the year ended June 30, 2007 increased by $3.9 million compared to R&D expenses of $22.8 million in fiscal year 2006. During fiscal year 2007, $21.2 million of the R&D expenses were focused on Viprinex(TM), with the remaining $5.5 million on XERECEPT. The increase in research and development expenses resulted from an additional $5.2 million of expenses incurred for the Phase 3 clinical trials of Viprinex, which was partially offset by a decrease of $1.3 million of reimbursed expenses for the continuing Phase 3 clinical trials for XERECEPT.

The Company had no acquired in-process research and development expenses for the fiscal year ended June 30, 2007 compared to $11.5 million for the fiscal year ended June 30, 2006. The 2006 expenses represented the expensing of certain tangible and intangible assets related to the acquisition of Empire Pharmaceuticals from 2005.

General and administrative expenses totaled $6.5 million for the year ended June 30, 2007 compared to $6.0 million in fiscal year 2006. The increase in general and administrative expenses resulted primarily from increases of approximately $362,000 for compensation, $259,000 for consultants and $276,000 for audit fees, offset by a $243,000 decrease in legal fees.

Investment income for the fiscal year ended June 30, 2007 totaled approximately $494,000 compared to $399,000 in fiscal year 2006. The increase was due to higher average cash balances in fiscal 2007 and an increase in our average rate of return on our investment portfolio.

Gain on change in value of warr
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 21, 2014 2014 Deep ... professional and in-depth research report on the transformer ... definition, classification, application, and industry chain structure as ... international market analysis, including China’s domestic market as ... & economic situation analysis. The report also covers ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... tech company may seem low on the priority scheme. Alternately, ... qualified people available. Neither is true. , ,The board ... mentor senior management. Eventually the board should become a entity ... the business. But at the very start, the only guarantee ...
... had the opportunity to attend an exciting Chicago networking event ... event featured a presentation by professor Alicia Loffler, who is ... at Northwestern University . , ,Lofflers presentation addressed the ... needed to make these clusters grow and prosper. , ...
... MILWAUKEE,WI.-Beware calling the next strange idea you hear strange: ... millionaire next door. , ,A panel of experienced ... Conference in Milwaukee last Wednesday have dealt with looks ... their brethren in the audience to accept the whispers ...
Cached Biology Technology:Board Pieces 2Board Pieces 3Board Pieces 4The Making of Chicago as a Biotech Cluster 2The Making of Chicago as a Biotech Cluster 3The Making of Chicago as a Biotech Cluster 4The Making of Chicago as a Biotech Cluster 5The Making of Chicago as a Biotech Cluster 6The Making of Chicago as a Biotech Cluster 7Lowering the fear factor for entrepreneurs, intra-preneurs 2Lowering the fear factor for entrepreneurs, intra-preneurs 3
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... a child, it was fascinating to put a flashlight ... through the hand. Washington University in St. Louis engineers ... the body,s tissues to improve imaging of cancerous tissues ... PhD, the Gene K. Beare Distinguished Professor of Biomedical ... is applying a novel time-reversal technology that allows researchers ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Drier conditions projected to result from climate change in ... result in increased dust storm activity in the future, ... U.S. Geological Survey and the University of California, Los ... soil measurements collected over a 20-year period in Arches ...
... of high quality data on climate change and its ... climate models do not always have access to this ... the Department of Energy, the on-the-ground information will get ... Energy and the Environment. The DOE-funded project, led ...
... to make currents visible is a common practice in ... adopted and perfected by artist Paul Matisse in sculptures ... object whose movement through the liquid creates whorls that ... object align with the direction of the current; light ...
Cached Biology News:DOE grant joins climate modeling with local, regional empirical data 2MIT scientists say ocean currents cause microbes to filter light 2
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... a cytochrome P450 (CYP450) metabolite postulated to ... and cerebral vasculature. In rat cerebral microvessels, ... autoregulatory vasoconstriction. 20-HETE is excreted mainly as ... 20-HETE (20-40 pg/ml in human urine) is ...
... enables you to insert a transposable element ... by in vitro transposition. It uses TnsABC* ... the DNA target. Target DNA may be ... depending on your interests (6-8). If the ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: